LQDA NASDAQ
Liquidia Corporation
1W: +4.5%
1M: +67.2%
3M: +84.5%
YTD: +97.4%
1Y: +264.1%
3Y: +725.2%
5Y: +2178.3%
$60.98
-0.99 (-1.60%)
Weekly Expected Move ±14.0%
$41
$49
$57
$65
$73
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$0.3M
Congress—
ETF Holdings—
Key Statistics
Market Cap$5.4B
52W Range11.85-62.3
Volume957,199
Avg Volume1,470,238
Beta0.42
Dividend—
Analyst Ratings
Company Info
CEORoger A. Jeffs
Employees170
SectorHealthcare
IndustryBiotechnology
IPO Date2018-07-26
Websiteliquidia.com
419 Davis Drive
Morrisville, NC 27560
US
Morrisville, NC 27560
US
919 328 4400
About Liquidia Corporation
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Latest News
Here's Why You Should Add Altimmune Stock to Your Portfolio Now
TEVA's MAA for Olanzapine LAI in Schizophrenia Accepted in the EU
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
Zacks.com featured highlights include Liquidia, Exxon Mobil, Valero Energy and Diamondback Energy
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| JEFFS ROGER | S-Sale | 25,000 | $61.30 | 2026-05-20 |
| JEFFS ROGER | S-Sale | 25,000 | $58.65 | 2026-05-19 |
| Caligan Partners LP | S-Sale | 5,300 | $59.98 | 2026-05-19 |
| Caligan Partners LP | P-Purchase | 5,300 | $59.98 | 2026-05-19 |
| JEFFS ROGER | S-Sale | 25,000 | $56.77 | 2026-05-18 |